Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species

Reference

• BEAVO, J. A., 1995, Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiological Reviews, 75, 725–748.
   PubMed Web of Science ®Google Scholar
• BENET, L. Z. and GALEAZZI, R. L., 1971, Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences, 68, 1071–1074.
   Web of Science ®Google Scholar
• BROWN, R. P., DELP, M. D., LINDSTEDT, S. L., RHOMBERG, L. R. and BELILES, R. P., 1997, Physiological parameter values for physiologically based pharmacokinetic models. Toxicological Industrial Health, 13, 407–484.
   PubMed Web of Science ®Google Scholar
• COMPTON, C. H., GUBB, J., NIEMAN, R., EDELSON, J., AMIT, 0., BAKST, A., AYRES, J. G., CREEMERS, J. P., SCHULTZE-WERNINGHAUS, G., BRAMBILLA, C. and BARNES, N. C., 2001, Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet, 358, 265–270.
   Google Scholar
• CVETKOVIC, M., LEAKE, B., FROMM, M. F., WILKINSON, G. R. and Kim, R. B., 1999, OATP and p-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition, 27, 866–871.
   PubMed Web of Science ®Google Scholar
• DAVIES, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
   PubMed Web of Science ®Google Scholar
• DOHERTY, A. M., 1999, Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Current Opinion in Chemical Biology, 3, 466–473.
   PubMedGoogle Scholar
• DYKE, H. J. and MONTANA, J. G., 2002, Update on the therapeutic potential of PDE4 inhibitors. Expert Opinion on Investigational Drugs, 11, 1–13.
   PubMed Web of Science ®Google Scholar
• ESSAYAN, D. M., 1999, Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochemical Pharmacology, 57, 965–973.
   PubMed Web of Science ®Google Scholar
• FRANCIS, S. H., TURKO, I. V. and CORBIN, J. D., 2001, Cyclic nucleotide phosphodiesterases: relating structure and function. Progress in Nucleic Acid Research and Molecular Biology, 65, 1–52.
   PubMed Web of Science ®Google Scholar
• FUKUTO, J. M., KUMAGAI, Y. and CHO, A. K., 1991, Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects. Journal of Medicinal Chemistry, 34, 2871–2876.
   PubMed Web of Science ®Google Scholar
• GAMBLE, E., GROOTENDORST, D. C., BRIGHTLING, C. E., TROY, S., QIU, Y., ZHU, J., PARKER, D., MATIN, D., MAJUMDAR, S., VIGNOLA, A. M., KROEGEL, C., MORELL, F., HANSEL, T. T., RENNARD, S. I., COMPTON, C., AMIT, 0., TAT, T., EDELSON, J., PAVORD, I. D., RABE, K. F., BARNES, N. C. and JEFFERY, P. K., 2003, Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 168, 976–982.
   Google Scholar
• GIEMBYCZ, M. A., 2001, Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs, 10, 1361–1379.
   PubMed Web of Science ®Google Scholar
• HA-DUONG, N. T., DIJOLS, S., MACHEREY, A. C., GOLDSTEIN, J. A., DANSETTE, P. M. and MANSUY, D., 2001, Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry, 40, 12112–12122.
   Google Scholar
• HEIENE, R. and MOE, L., 1998, Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review. Journal of Veterinary Internal Medicine, 12, 401–414.
   PubMedGoogle Scholar
• HIRAMATSU, M., KUMAGAI, Y., UNGER, S. E. and CHO, A. K., 1990, Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. Journal of Pharmacology and Experimental Therapeutics, 254, 521–527.
   PubMed Web of Science ®Google Scholar
• KIM, R. B., 2002, Transporters and xenobiotic disposition. Toxicology, 181–182, 291–297.
   Google Scholar
• LOPEZ-GARCIA, M. P., DANSETTE, P. M. and MANSUY, D., 1994, Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry, 33, 166–175.
   Google Scholar
• MAHMOOD, I. and BALIAN, J. D., 1996, Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica, 26, 887–895.
   PubMed Web of Science ®Google Scholar
• MANGANIELLO, V. C., MURATA, T., TAIRA, M., BELFRAGE, P. and DEGERMAN, E., 1995, Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Archives of Biochemistry and Biophysics, 322, 1–13.
   PubMed Web of Science ®Google Scholar
• MARFAT, A., HUNTER, K., CHENG, J. B., PILLAR, J. S., MAGEE, T. V., KUDLACZ, E. M., KALGUTKAR, A. S., TAYLOR, T. J. and WATSON, J. W., 2004 (in preparation).
   Google Scholar
• MARTIN, T. J., 2001, PDE4 inhibitors — a review of the recent patent literature. Investigational drugs, 4, 312–338.
   Google Scholar
• MAYHEW, B. S., JONES, D. R. and HALL, S. D., 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition, 28, 1031–1037.
   PubMed Web of Science ®Google Scholar
• MULLER, T., ENGELS, P. and FOZARD, J. R., 1996, Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends in Pharmacological Sciences, 17, 294–298.
   PubMed Web of Science ®Google Scholar
• MURRAY, M., 2000, Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Current Drug Metabolism, 1, 67-84. NORMAN, P., 2000, PDE4 inhibitors: sustained patenting activity as leading drugs near the market. Expert Opinion on Therapeutic Patents, 10, 1415–1427.
   Google Scholar
• OBACH, R. S., 2000, Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, a herbal preparation used in the treatment of depression. Journal of Pharmacology and Experimental Therapeutics, 294, 88–95.
   PubMed Web of Science ®Google Scholar
• OIE, S. and TOZER, T. N., 1979, Effect of altered plasma protein binding on apparent volume of distribution. Journal of Pharmaceutical Sciences, 68, 1203–1205.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• RACHA, J. K., RETTIE, A. E. and KUNZE, K. L., 1998, Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry, 37, 7407–7419.
   PubMed Web of Science ®Google Scholar
• SAWADA, Y., HANANO, M., SUGIYAMA, Y. and IGA, T., 1984, Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics Biopharmaceutical, 12, 241–261.
   PubMedGoogle Scholar
• SHIPKOVA, M., ARMSTRONG, V. W., DELLERICH, M. and WIELAND, E., 2003, Acyl glucuronide drug metabolites: toxicological and analytical implications. Therapeutic Drug Monitoring, 25, 1–16.
   PubMed Web of Science ®Google Scholar
• SOUNESS, J. E., ALDOUS, D. and SARGENT, C., 2000, Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology, 47, 127–162.
   PubMed Web of Science ®Google Scholar
• SUZUKI, H., KNELLER, B., HAINING, R. L., TRAGER, W. F. and RETTIE, A. E., 2002, (±)-N-3-benzylnirvanol and (—)-N-3-benzyl-phenoparbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition, 30, 235–239.
   PubMed Web of Science ®Google Scholar
• TILL, A. E. and BENET, L. Z., 1979, Pseudoephedrine pharmacokinetics in the rat using a microanalysis technique. Pharmacology, 18, 306–310.
   PubMed Web of Science ®Google Scholar
• WALSKY, R. L. and °BACH, R. S., 2003, Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metabolism and Disposition, 31, 343.
   Google Scholar
• ZELLER, E., STIEF, H. J., PFLUG, B. and SASTRE-Y-HERNANDEZ, M., 1984, Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry, 17, 188–190.
   Google Scholar
• ZUSSMAN, B. D., BENINCOSA, L. J., WEBBER, D. M., CLARK, D. J., COWLEY, H., KELLY, J., MURDOCH, R. D., UPWARD, J., WYLD, P., PORT, A. and FUDER, H., 2001a, An overview of the pharmacokinetics of cilomilast (Arifio), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. Journal of Clinical Pharmacology, 41, 950–958.
   PubMed Web of Science ®Google Scholar
• ZUSSMAN, B. D., DAVIE, C. C., KELLY, J., MURDOCH, R. D., CLARK, D. J., SCHOFIELD, J. P., WALLS, C., BIRRELL, C., WEBBER, D., QUINLAN, J., RITCHIE, S. Y. and CARR, A., 2001b, Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy, 21, 653–660.
   PubMed Web of Science ®Google Scholar